T1	Participants 441 483	581 patients who enrolled in the extension
T2	Participants 318 405	714 patients who received etanercept in one of 7 initial trials or a longterm extension
T3	Participants 500 649	714 patients enrolled in the initial trials, 581 (81%) enrolled in the extension, and 388 (54%) patients are continuing to receive etanercept therapy
